Free Trial Information
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...will be acting interim principal financial officer. Baker previously served as VP of finance at Cleave Biosciences...
Read More
BioCentury | Dec 24, 2019
Company News

Rival suitor could have pressed Synthorx takeout price even higher than winning $2.5B Sanofi bid

...and CEO is Laura Shawver, who joined in November 2017 after serving as CEO of Cleave Biosciences Inc....
Read More
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...and CEO is Laura Shawver, who joined in November 2017 after serving as CEO of Cleave Biosciences Inc....
Read More
BioCentury | Aug 7, 2019
Financial News

VCs recapitalize Cleave around next-gen molecule

...second-generation cancer compound following a toxicity snag for the company's first-generation version. Formerly known as Cleave Biosciences Inc....
Read More
BioCentury | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

...short half-lives. Shawver joined Synthorx in late 2017; she previously was CEO and director of Cleave Biosciences Inc....
...and Institutions Mentioned Ambrx Inc., La Jolla, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cleave Biosciences Inc....
Read More
BioCentury | Nov 28, 2017
Company News

Management Tracks: Synthorx, Vir

...Jolla, Calif.) hired Laura Shawver as president, CEO and a director. She was CEO of Cleave Biosciences Inc....
Read More
BioCentury | Aug 22, 2017
Company News

Management tracks: Akari, Turnstone, Iconic

...company Atara Biotherapeutics Inc. (NASDAQ:ATRA) appointed Kanya Rajangam CMO and SVP. She was CMO at Cleave Biosciences Inc....
Read More
BioCentury | Feb 28, 2017
Clinical News

Caltech group finds proteasome inhibitor with novel MOA

...California Institute of Technology , was founder of Proteolix Inc. , which created carfilzomib, and Cleave Biosciences Inc....
Read More
BioCentury | Jan 7, 2017
Company News

Management tracks

...who left the company. Young was CFO and treasurer at OvaScience Inc. (NASDAQ:OVAS). Oncology company Cleave Biosciences Inc....
Read More
BioCentury | Aug 15, 2016
Finance

De-risking first in class

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083 . Now, the biotech has attracted a cadre of new investors in last...
Read More
Items per page:
1 - 10 of 33
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...will be acting interim principal financial officer. Baker previously served as VP of finance at Cleave Biosciences...
Read More
BioCentury | Dec 24, 2019
Company News

Rival suitor could have pressed Synthorx takeout price even higher than winning $2.5B Sanofi bid

...and CEO is Laura Shawver, who joined in November 2017 after serving as CEO of Cleave Biosciences Inc....
Read More
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...and CEO is Laura Shawver, who joined in November 2017 after serving as CEO of Cleave Biosciences Inc....
Read More
BioCentury | Aug 7, 2019
Financial News

VCs recapitalize Cleave around next-gen molecule

...second-generation cancer compound following a toxicity snag for the company's first-generation version. Formerly known as Cleave Biosciences Inc....
Read More
BioCentury | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

...short half-lives. Shawver joined Synthorx in late 2017; she previously was CEO and director of Cleave Biosciences Inc....
...and Institutions Mentioned Ambrx Inc., La Jolla, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Cleave Biosciences Inc....
Read More
BioCentury | Nov 28, 2017
Company News

Management Tracks: Synthorx, Vir

...Jolla, Calif.) hired Laura Shawver as president, CEO and a director. She was CEO of Cleave Biosciences Inc....
Read More
BioCentury | Aug 22, 2017
Company News

Management tracks: Akari, Turnstone, Iconic

...company Atara Biotherapeutics Inc. (NASDAQ:ATRA) appointed Kanya Rajangam CMO and SVP. She was CMO at Cleave Biosciences Inc....
Read More
BioCentury | Feb 28, 2017
Clinical News

Caltech group finds proteasome inhibitor with novel MOA

...California Institute of Technology , was founder of Proteolix Inc. , which created carfilzomib, and Cleave Biosciences Inc....
Read More
BioCentury | Jan 7, 2017
Company News

Management tracks

...who left the company. Young was CFO and treasurer at OvaScience Inc. (NASDAQ:OVAS). Oncology company Cleave Biosciences Inc....
Read More
BioCentury | Aug 15, 2016
Finance

De-risking first in class

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083 . Now, the biotech has attracted a cadre of new investors in last...
Read More
Items per page:
1 - 10 of 33